- Discover
- /
- TNFA
Sagehood
Financial Analyst
PREMIUM
Technical Trader
PREMIUM
Valuation Projection
PREMIUM
Social Media Buzz
PREMIUM
News Agent
PREMIUM
Macro Economist
PREMIUM
About TNFA
9/22/2025
Comprehensive Analysis
Financial Health
- Liquidity and Capital Structure: TNF Pharmaceuticals (TNFA) maintains a current ratio of 1.7 and a quick ratio of 1.27, indicating moderate short-term liquidity. However, the company’s reliance on financing inflows (e.g., $14.69M in Q3 2023) to fund operations highlights structural cash-burn dynamics. Post-reverse split, the float is concentrated at 1.8 million shares, amplifying liquidity risks.
Free Insights for Smarter Investing
Get 5 daily AI-powered insights on your favorite stocks-absolutely free.
Free Account
- View 5 tickers daily
- Create and manage Watchlists
- Import portfolios (no personalized insights)
- Chat with the general Sagehood AI Agent
- Market Radar: Preview access only
Premium Membership
- Unlimited AI-generated insights across all sections
- Market Overview
- Market Radar (AI-driven investment opportunities)
- Access to all Sagehood AI agents, including domain-specific experts
- Personalized insights and actionable recommendations for smarter investing